The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 07, 2022

Filed:

Feb. 28, 2019
Applicant:

Metabasis Therapeutics, Inc., San Diego, CA (US);

Inventors:

Jorge E Gomez-Galeno, San Diego, CA (US);

Scott J. Hecker, Del Mar, CA (US);

Qun Dang, San Diego, CA (US);

Mali Venkat Reddy, San Diego, CA (US);

Zhili Sun, San Diego, CA (US);

Matthew P. Grote, Carlsbad, CA (US);

Thanh Huu Nguyen, Solana Beach, CA (US);

Robert Huerta Lemus, Escondido, CA (US);

Haiqing Li, San Diego, CA (US);

Assignee:

Metabasis Therapeutics, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 309/15 (2006.01); C07D 263/57 (2006.01); A61K 31/185 (2006.01); A61K 31/423 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07C 309/15 (2013.01); A61K 31/185 (2013.01); A61K 31/423 (2013.01); A61K 45/06 (2013.01); C07D 263/57 (2013.01); C07B 2200/07 (2013.01); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05);
Abstract

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof. Formula I


Find Patent Forward Citations

Loading…